- Home
- SSTI vs ZNTL Comparison
SSTI vs ZNTL Comparison
Compare SSTI & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SSTI | ZNTL |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.0M | 118.3M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SSTI | ZNTL |
|---|---|---|
| Price | $7.79 | $2.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $15.80 | $5.87 |
| AVG Volume (30 Days) | 180.2K | ★ 2.6M |
| Earning Date | 02-24-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $102,749,000.00 | $26,865,000.00 |
| Revenue This Year | $3.98 | N/A |
| Revenue Next Year | $9.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.78 | $1.01 |
| 52 Week High | $19.43 | $3.95 |
Technical Indicators
Market Signals| Indicator | SSTI | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 66.51 |
| Support Level | $7.94 | $1.31 |
| Resistance Level | $8.83 | $3.95 |
| Average True Range (ATR) | 0.53 | 0.37 |
| MACD | -0.06 | 0.14 |
| Stochastic Oscillator | 14.94 | 62.50 |
Price Performance
Historical ComparisonAbout SSTI SoundThinking Inc.
SoundThinking Inc is a public safety technology company that combines transformative solutions and strategic advisory services for law enforcement and civic leadership. Its flagship SafetySmart platform includes ShotSpotter, the acoustic gunshot detection system, CrimeTracer, the foremost law enforcement search engine, CaseBuilder, a one-stop investigation management system, and ResourceRouter, software that directs patrol and community anti-violence resources to help maximize their impact.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.